PAX-2在子宫内膜增生性病变和I型子宫内膜癌中的表达及意义
|
摘要
目的:探讨PAX-2在子宫内膜增生性病变及I型子宫内膜癌中的表达及意义。方法:收集正常增殖期子宫内膜31例、良性子宫内膜增生107例、子宫内膜上皮内瘤变58例、子宫内膜样癌76例,采用免疫组织化学法检测PAX-2在上述病变中的表达。结果:PAX-2在上述4组病变组织中的正常表达率逐渐降低,分别为77.4%(24/31),7.5%(8/107),1.7%(1/58),0.0%(0/76),差异有统计学意义(χ~2=142.512,P<0.01)。结论:PAX-2表达缺失参与子宫内膜样癌的发生,而且是其早期事件。PAX-2表达缺失不能作为子宫内膜增生性病变的标志物,但完全缺失可以作为标志物。
Objective: To investigate the expression of PAX-2 in endometrial hyperplastic lesions and type I endometrial carcinoma and its significance. Methods: Thirty-one cases of normal proliferative endometrium, 107 cases of benign hyperplastic endometrium, 58 cases of endometrioid intraepithelial neoplasia, and 76 cases of endometrioid carcinoma were enrolled. PAX-2 expression was detected by immunohistochemistry in the above mentioned lesions. Results: The normal expression rates of PAX-2 were gradually decreased in proliferative endometrium, benign hyperplastic endometrium, endometrioid intraepithelial neoplasia, and endometrioid carcinoma, with the rates of 77.4%(24/31), 7.5%(8/107), 1.7%(1/58), 0.0%(0/76), respectively. The difference was statistically significant(χ~2=142.512, P<0.01). Conclusion: The loss of PAX-2 expression plays an important role in the carcinogenesis of endometrioid carcinoma and is an early event. The complete loss of PAX-2 expression is a reliable marker of endometrial hyperplastic lesions rather than the loss of PAX-2 expression.
Objective: To investigate the expression of PAX-2 in endometrial hyperplastic lesions and type I endometrial carcinoma and its significance. Methods: Thirty-one cases of normal proliferative endometrium, 107 cases of benign hyperplastic endometrium, 58 cases of endometrioid intraepithelial neoplasia, and 76 cases of endometrioid carcinoma were enrolled. PAX-2 expression was detected by immunohistochemistry in the above mentioned lesions. Results: The normal expression rates of PAX-2 were gradually decreased in proliferative endometrium, benign hyperplastic endometrium, endometrioid intraepithelial neoplasia, and endometrioid carcinoma, with the rates of 77.4%(24/31), 7.5%(8/107), 1.7%(1/58), 0.0%(0/76), respectively. The difference was statistically significant(χ~2=142.512, P<0.01). Conclusion: The loss of PAX-2 expression plays an important role in the carcinogenesis of endometrioid carcinoma and is an early event. The complete loss of PAX-2 expression is a reliable marker of endometrial hyperplastic lesions rather than the loss of PAX-2 expression.
引文
1.Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CACancer J Clin,2015,65(2):87-108.
2.Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China,2013[J].Cancer Lett,2017,401:63-71.
3.Kurman RJ,Carcangiu ML,Herrington CS,et al.WHO classification of tumours of female reproductive organs[M].Lyon:IARC,4th Edition,1014,125-130.
4.徐中海.Pax-2蛋白在子宫内膜癌中的表达及其临床意义[J].湖北民族学院学报(医学版),2017,34(4):15-17.XU Zhonghai.Expression of Pax-2 protein in endometrial carcinoma and its clinical significance[J].Journal of Hubei University for Nationalities.Medical Edition,2017,34(4):15-17.
5.孟轶婷,马东林,李莉,等.PAX-2和PTEN在子宫内膜病变中的表达及其与子宫内膜上皮内瘤变的相关性[J].肿瘤研究与临床,2017,29(1):27-31.MENG Yiting,MA Donglin,LI Li,et al.Expression of Pax-2 and PTEN in endometrial lesions and their correlation with endometrial intraepithelial neoplasia[J].Cancer Research and Clinic,2017,29(1):27-31.
6.Allison KH,Upson K,Reed SD,et al.PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia[J].Int J Gynecol Pathol,2012,31(2):151-159.
7.朱颖,叶琇锦.PAX2基因与肿瘤关系的研究进展[J].实用肿瘤杂志,2015,30(3):295-298.ZHU Ying,YE Xiujin.The update on the relation between PAX2 and tumor[J].Journal of Practical Oncology,2015,30(3):295-298.
8.杨达荣,杨柳.PAX2在女性生殖系统肿瘤中的表达及其临床意义[J].医药前沿,2014,16,352-353.YANG Darong,YANG Liu.Expression of PAX2 in the neoplasms of female reproduction system and its clinical significance[J].Journal of Frontiers of Medicine,2014,16,352-353.
9.Monte NM,Webster1 KA,Neuberg D,et al.Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer[J].Cancer Res,2010,70(15):6225-6232.
10.Joiner AK,Quick CM,Jeffus SK.Pax2 expression in simultaneously diagnosed WHO and EIN classification systems[J].Int J Gynecolo Pathology,2015,3(1):40-46.
11.Kahraman K,Kiremitci S,Taskin S,et al.Expression pattern of PAX2in hyperplastic and malignant endometrium[J].Arch Gynecol Obstet,2012,286(1):173-178.
12.尚立娜,刘玮,李波,等.PAX2在I型子宫内膜癌及其癌前病变中的表达及意义[J].甘肃医药,2015,34(5):324-327.SHANG Lina,LIU Wei,LI Bo,et al.Expression and significance of PAX2 in type I endometrial carcinoma and precancers[J].Gansu Medical Journal,2015,34(5):324-327.
13.王冬,崔俊琪,马爱国,等.P16、P63、PAX-2在子宫内膜癌中的作用及临床意义[J].中国生育健康杂志,2015,25(Z1):35-37.WANG Dong,CUI Junqi,MA Aiguo,et al.Expression and significance of P16,P63,and PAX2 in endometrial carcinoma[J].Chinese Journal of Reproductivity Health,2015,25(Supple 1):35-37.
14.王肃静,陆香凤,黄炳臣,等.配对盒基因2和CD44基因在子宫内膜癌中的表达及意义[J].右江医学,2016,44(4):388-382.WANG Sujing,LU Xiangfeng,HUANG Bingchen,et al.Expression and significance of PAX2 and CD44 in endometrial carcinoma[J].Youjiang Medical Journal,2016,44(4):388-382.
2.Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China,2013[J].Cancer Lett,2017,401:63-71.
3.Kurman RJ,Carcangiu ML,Herrington CS,et al.WHO classification of tumours of female reproductive organs[M].Lyon:IARC,4th Edition,1014,125-130.
4.徐中海.Pax-2蛋白在子宫内膜癌中的表达及其临床意义[J].湖北民族学院学报(医学版),2017,34(4):15-17.XU Zhonghai.Expression of Pax-2 protein in endometrial carcinoma and its clinical significance[J].Journal of Hubei University for Nationalities.Medical Edition,2017,34(4):15-17.
5.孟轶婷,马东林,李莉,等.PAX-2和PTEN在子宫内膜病变中的表达及其与子宫内膜上皮内瘤变的相关性[J].肿瘤研究与临床,2017,29(1):27-31.MENG Yiting,MA Donglin,LI Li,et al.Expression of Pax-2 and PTEN in endometrial lesions and their correlation with endometrial intraepithelial neoplasia[J].Cancer Research and Clinic,2017,29(1):27-31.
6.Allison KH,Upson K,Reed SD,et al.PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia[J].Int J Gynecol Pathol,2012,31(2):151-159.
7.朱颖,叶琇锦.PAX2基因与肿瘤关系的研究进展[J].实用肿瘤杂志,2015,30(3):295-298.ZHU Ying,YE Xiujin.The update on the relation between PAX2 and tumor[J].Journal of Practical Oncology,2015,30(3):295-298.
8.杨达荣,杨柳.PAX2在女性生殖系统肿瘤中的表达及其临床意义[J].医药前沿,2014,16,352-353.YANG Darong,YANG Liu.Expression of PAX2 in the neoplasms of female reproduction system and its clinical significance[J].Journal of Frontiers of Medicine,2014,16,352-353.
9.Monte NM,Webster1 KA,Neuberg D,et al.Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer[J].Cancer Res,2010,70(15):6225-6232.
10.Joiner AK,Quick CM,Jeffus SK.Pax2 expression in simultaneously diagnosed WHO and EIN classification systems[J].Int J Gynecolo Pathology,2015,3(1):40-46.
11.Kahraman K,Kiremitci S,Taskin S,et al.Expression pattern of PAX2in hyperplastic and malignant endometrium[J].Arch Gynecol Obstet,2012,286(1):173-178.
12.尚立娜,刘玮,李波,等.PAX2在I型子宫内膜癌及其癌前病变中的表达及意义[J].甘肃医药,2015,34(5):324-327.SHANG Lina,LIU Wei,LI Bo,et al.Expression and significance of PAX2 in type I endometrial carcinoma and precancers[J].Gansu Medical Journal,2015,34(5):324-327.
13.王冬,崔俊琪,马爱国,等.P16、P63、PAX-2在子宫内膜癌中的作用及临床意义[J].中国生育健康杂志,2015,25(Z1):35-37.WANG Dong,CUI Junqi,MA Aiguo,et al.Expression and significance of P16,P63,and PAX2 in endometrial carcinoma[J].Chinese Journal of Reproductivity Health,2015,25(Supple 1):35-37.
14.王肃静,陆香凤,黄炳臣,等.配对盒基因2和CD44基因在子宫内膜癌中的表达及意义[J].右江医学,2016,44(4):388-382.WANG Sujing,LU Xiangfeng,HUANG Bingchen,et al.Expression and significance of PAX2 and CD44 in endometrial carcinoma[J].Youjiang Medical Journal,2016,44(4):388-382.